ATAD5 expression based on
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Comparison | Statistical significance |
Normal-vs-Primary | 1.0040002162981E-10 |
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Stage1 |
1.39139999999482E-06 |
Normal-vs-Stage2 |
1.940630E-03 |
Normal-vs-Stage3 |
N/A |
Normal-vs-Stage4 |
1.830480E-02 |
Stage1-vs-Stage2 |
7.552600E-01 |
Stage1-vs-Stage3 |
N/A |
Stage1-vs-Stage4 |
6.635800E-01 |
Stage2-vs-Stage3 |
N/A |
Stage2-vs-Stage4 |
8.922000E-01 |
Stage3-vs-Stage4 |
N/A |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Caucasian |
3.31890004368063E-09 |
Normal-vs-AfricanAmerican |
3.466400E-01 |
Normal-vs-Asian |
9.344300E-02 |
Caucasian-vs-AfricanAmerican |
5.942800E-01 |
Caucasian-vs-Asian |
9.619000E-01 |
AfricanAmerican-vs-Asian |
7.019200E-01 |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Male |
3.79430000000403E-05 |
Normal-vs-Female |
1.37730000004943E-06 |
Male-vs-Female |
6.696400E-01 |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Patient BMI information is not available for 1 sample.
Descriptions |
Normal weight |
BMI greater than equal to 18.5 and BMI less than 25 |
Extereme weight |
BMI greater than equal to 25 and BMI less than 30 |
Obese |
BMI greater than equal to 30 and BMI less than 40 |
Extreme Obese |
BMI greater than 40 |
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Normal_Weight |
1.555490E-03 |
Normal-vs-Extreme_Weight |
6.29300000000166E-05 |
Normal-vs-Obese |
1.675560E-03 |
Normal-vs-Extreme_Obese |
N/A |
Normal_Weight-vs-Extreme_Weight |
3.678200E-01 |
Normal_Weight-vs-Obese |
1.147980E-01 |
Normal_Weight-vs-Extreme_Obese |
N/A |
Extreme_Weight-vs-Obese |
4.639800E-01 |
Extreme_Weight-vs-Extreme_Obese |
N/A |
Obese-vs-Extreme_Obese |
N/A |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Age(21-40Yrs) |
1.057590E-01 |
Normal-vs-Age(41-60Yrs) |
4.634000E-04 |
Normal-vs-Age(61-80Yrs) |
1.79560000002077E-06 |
Normal-vs-Age(81-100Yrs) |
3.543600E-01 |
Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.985800E-01 |
Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.281200E-01 |
Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.926200E-01 |
Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.430600E-01 |
Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.838800E-01 |
Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.979200E-01 |
|
|
CHOL : Cholangiocarcinoma
Subtype descriptions |
Grade 1 | Well differentiated (low grade) |
Grade 2 | Moderately differentiated (intermediate grade) |
Grade 3 | Poorly differentiated (high grade) |
Grade 4 | Undifferentiated (high grade) |
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Grade 1 |
N/A |
Normal-vs-Grade 2 |
5.617400E-01 |
Normal-vs-Grade 3 |
7.322800E-01 |
Normal-vs-Grade 4 |
1.000000E+00 |
Grade 1-vs-Grade 2 |
N/A |
Grade 1-vs-Grade 3 |
N/A |
Grade 1-vs-Grade 4 |
N/A |
Grade 2-vs-Grade 3 |
4.504300E-02 |
Grade 2-vs-Grade 4 |
5.617400E-01 |
Grade 3-vs-Grade 4 |
7.322800E-01 |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 5 samples.
pathologic_N descriptions |
N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-N0 |
6.40330000134526E-08 |
Normal-vs-N1 |
1.761990E-02 |
N0-vs-N1 |
1.174570E-01 |
|
|